15 Aug Armatus Bio

Posted at 19:08h in by Brittany Miller

Rachel Salzman, CEO

Oct. 9 | 11:45am | FLW Ballroom G

Columbus OH

(Private)

Armatus Bio, a late preclinical stage company, is developing best-in-class vectorized RNAi therapeutics with technology licensed from Nationwide Children’s Hospital with the goal of addressing urgent unmet needs in genetically-driven neurological diseases. The company is advancing a lead candidate targeting Charcot-Marie-Tooth Type 1A (CMT1A) that is targeting an IND submission in 2025, and a second program for Facioscapulohumeral Muscular Dystrophy (FSHD).

www.armatusbio.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 6-8, 2025
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions